AI Article Synopsis
- Osteoclast differentiation is crucial for bone resorption and involves the fusion of osteoclasts and their precursors.
- Osteoprotegerin (OPG) inhibits this differentiation and fusion by affecting specific molecular markers and subcellular localization in osteoclasts and precursors.
- ATP can counteract OPG's inhibitory effects, indicating a potential regulatory pathway that could be targeted for therapies related to bone metabolism.
Article Abstract
Osteoclast (OC) differentiation, vital for bone resorption, depends on osteoclast and precursor fusion. Osteoprotegerin (OPG) inhibits osteoclast differentiation. OPG's influence on fusion and mechanisms is unclear. Osteoclasts and precursors were treated with OPG alone or with ATP. OPG significantly reduced OC number, area and motility and ATP mitigated OPG's inhibition. However, OPG hardly affected the motility of precusors. OPG downregulated fusion-related molecules (CD44, CD47, DC-STAMP, ATP6V0D2) in osteoclasts, reducing only CD47 in precursors. OPG reduced Connexin43 phosphorylated forms (P1 and P2) in osteoclasts, affecting only P2 in precursors. OPG disrupted subcellular localization of CD44, CD47, DC-STAMP, ATP6V0D2, and Connexin43 in both cell types. Findings underscore OPG's multifaceted impact, inhibiting multinucleated osteoclast and mononuclear precursor fusion through distinct molecular mechanisms. Notably, ATP mitigates OPG's inhibitory effect, suggesting a potential regulatory role for the ATP signaling pathway. This study enhances understanding of intricate processes in osteoclast differentiation and fusion, offering insights into potential therapeutic targets for abnormal bone metabolism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diff.2024.100789 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular and pharmacological heterogeneity of ETV6::RUNX1 acute lymphoblastic leukemia.
Nat Commun
January 2025
Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
ETV6::RUNX1 is the most common fusion gene in childhood acute lymphoblastic leukemia (ALL) associated with favorable prognosis, but the optimal therapy for this subtype remains unclear. Profiling the genomic and pharmacological landscape of 194 pediatric ETV6::RUNX1 ALL cases, we uncover two transcriptomic clusters, C1 (61%) and C2 (39%). Compared to C1, the C2 subtype features higher white blood cell counts and younger age at diagnosis, as well as better early treatment responses.
View Article and Find Full Text PDFVenetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the gene: a case report and literature review.
Front Immunol
January 2025
Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
B-cell acute lymphoblastic leukemia (B-ALL) with the fusion gene has a poor prognosis, and the mortality rate exceeds 90%, particularly in cases of extramedullary relapse (EMR). Herein, we present a case of a 46-year-old male patient who developed relapsed B-ALL with . The patient initially achieved a complete remission (CR) after induction therapy and underwent haploidentical hematopoietic stem cell transplantation.
View Article and Find Full Text PDFLight-up lipid droplets dynamic behaviors using rationally designed carbon dots.
Talanta
January 2025
Institute of Environmental Science and School of Chemistry and Chemical Engineering, Shanxi University, Taiyuan, 030006, China. Electronic address:
Article Synopsis
- Lipid droplets (LDs) are crucial organelles for lipid storage and metabolism in cells, and imaging them can reveal their biological roles.
- Researchers developed LD-targeted carbon dots (LD-CDs) using a Schiff base reaction, which exhibit strong sensitivity to changes in solvent polarity due to their unique charge transfer characteristics.
- These LD-CDs not only specifically illuminate LDs and distinguish cancer cells from normal ones but also track dynamic cellular processes like lipophagy and lipid metabolism in living cells and zebrafish.
Characteristics and outcomes of secondary acute lymphoblastic leukemia (sALL) after multiple myeloma (MM): SEER data analysis in a single-center institution.
Cancer Pathog Ther
January 2025
Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
Background: Secondary acute lymphoblastic leukemia (sALL) is rare in patients diagnosed with antecedent multiple myeloma (MM). This study aimed to elucidate the clinical features and outcomes of patients with sALL after MM.
Methods: We conducted this population-based study using the Surveillance, Epidemiology, and End Results (SEER) database and retrospectively reviewed patients with sALL following MM treatment at our institution.
The ISC machinery assembles [2Fe-2S] clusters by formation and fusion of [1Fe-1S] precursors.
Nat Chem Biol
January 2025
Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette, France.
Iron-sulfur clusters are essential metallocofactors synthesized by multiprotein machineries via an unclear multistep process. Here we report a step-by-step dissection of the [2Fe-2S] cluster assembly process by the Escherichia coli iron-sulfur cluster (ISC) assembly machinery using an in vitro reconstituted system and a combination of biochemical and spectroscopic techniques. We show that this process is initiated by iron binding to the scaffold protein IscU, which triggers persulfide insertion by the cysteine desulfurase IscS upon the formation of a complex with IscU.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!